Immatics (IMTX) Total Current Liabilities (2019 - 2026)
Immatics (IMTX) posted Total Current Liabilities of $50.1 million for Q4 2025, down 31.21% sequentially from $72.8 million in Q3 2025, and down 31.08% YoY from $72.7 million in Q4 2024.
Analysis
Immatics (IMTX) Total Current Liabilities (2019 - 2026) Analysis & Trends
Immatics has reported Total Current Liabilities for 7 years, with the latest figure at $50.1 million in Q4 2025.
- Quarterly Total Current Liabilities fell 31.08% year-over-year to $50.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $50.1 million (down 31.08% YoY) and the FY2025 annual result came in at $48.6 million, down 33.96% from the prior year.
- Total Current Liabilities eased to $50.1 million in Q4 2025 per IMTX's latest filing, from $72.8 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $168.4 million in Q4 2023 and troughed at $50.1 million in Q4 2025.
- A 5-year average of $111.9 million and a median of $111.0 million in 2021 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities surged 55.09% in 2023, then tumbled 63.78% in 2025.
- Over 5 years, Total Current Liabilities stood at $108.8 million in 2021, then fell by 0.22% to $108.6 million in 2022, then soared by 55.09% to $168.4 million in 2023, then plunged by 56.87% to $72.7 million in 2024, then tumbled by 31.08% to $50.1 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $50.1 million, $72.8 million, and $64.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | 66.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 66.20 Mn |
| Mar 31, 2026 | 64.68 Mn |
| Dec 31, 2025 | 50.07 Mn |
| Sep 30, 2025 | 72.78 Mn |
| Jun 30, 2025 | 64.80 Mn |
| Mar 31, 2025 | 58.66 Mn |
| Dec 31, 2024 | 72.65 Mn |
| Sep 30, 2024 | 141.57 Mn |
| Jun 30, 2024 | 161.04 Mn |
| Mar 31, 2024 | 161.98 Mn |
| Dec 31, 2023 | 168.44 Mn |
| Sep 30, 2023 | 131.88 Mn |
| Jun 30, 2023 | 135.36 Mn |
| Mar 31, 2023 | 107.96 Mn |
| Dec 31, 2022 | 108.61 Mn |
| Sep 30, 2022 | 125.15 Mn |
| Jun 30, 2022 | 121.64 Mn |
| Mar 31, 2022 | 103.09 Mn |
| Dec 31, 2021 | 108.85 Mn |
| Sep 30, 2021 | 126.33 Mn |